About Aegerion
Aegerion is a company based in Cambridge (United States) founded in 2005 was acquired by Amryt Pharma in May 2019. Aegerion has raised $58.42 million across 7 funding rounds from investors including Amryt Pharma, MVM Partners and QLT. The company has 63 employees as of December 31, 2021. Aegerion has completed 1 acquisition, including Myalept. Aegerion operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 63 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aegerion Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$58.42 M (USD)
in 7 rounds
-
Latest Funding Round
$72.5 M (USD), Debt – Conventional
Nov 01, 2018
-
Investors
Amryt Pharma
& 9 more
-
Employee Count
63
as on Dec 31, 2021
- Investments & Acquisitions
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aegerion
Aegerion has successfully raised a total of $58.42M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $72.5 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aegerion
Aegerion has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Amryt Pharma, MVM Partners and QLT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Investment opportunities in healthcare are managed by Broadfin Capital.
|
Locked | Locked | Locked | |
|
Private equity firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Aegerion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aegerion
Aegerion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Myalept.
Investment portfolio details for Aegerion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Leptin replacement therapy is provided for generalized lipodystrophy patients.
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Aegerion
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aegerion
Detailed financials for Aegerion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aegerion Comparisons
Peer comparison for Aegerion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aegerion
Aegerion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
Detailed competitors of Aegerion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aegerion
Complete news archive for Aegerion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aegerion
Aegerion was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Aegerion is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Aegerion is a funded company, having raised a total of $58.42M across 7 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Aegerion is 63.
Aegerion Pharmaceuticals was established in 2005 in Cambridge, United States, within the biopharmaceutical sector. Treatments for cardiovascular and metabolic diseases are developed, including Juxtapid, which lowers low-density lipoprotein cholesterol levels, and Myalept, acquired from AstraZeneca for 325 million to address leptin deficiency complications in generalized lipodystrophy patients. Emphasis is given to solutions for hyperlipidemia assessment and management.
Aegerion's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Aegerion has made 1 acquisition, including Myalept.
Aegerion has 10 investors. Key investors include Amryt Pharma, MVM Partners, QLT, Athyrium Capital Management, and Highbridge.